Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Marstacimab Prefilled Syringe vs Prefilled Pen in Healthy Men
NCT04832139Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Mar 2021
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of marstacimab in hemophilia A and hemophilia B (HB) (2 arms), sponsored by Pfizer. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero Extrapolated to Infinite Time and Maximum Observed Plasma Concentration. Started Mar 2021; status: terminated.
02
Drugs
marstacimab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT04832139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04832139.